文献速递糖尿病肥胖与代谢综合征

减重改善严重肥胖合并空腹血糖受损者的β细胞功能

Weight Loss Improves β-Cell Function in People With Severe Obesity and Impaired Fasting Glucose: A Window of Opportunity.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

研究纳入58例BMI≥35 kg/m²的肥胖者(14例NFG、24例IFG、20例T2DM)及13例正常体重NFG者,行混合餐耐量试验评估胰岛素敏感性、分泌及β细胞功能。短期减重20 kg后NFG和IFG者β细胞功能改善,2年时IFG者仍优于基线,提示IFG是减重获益的窗口人群。

要点

  • 严重肥胖合并IFG者短期减重可改善β细胞功能
  • 减重20 kg后IFG者β细胞功能改善趋势持续至2年
  • IFG可能是减重改善β细胞功能的最佳窗口人群

核心结论

  • 短期减重改善NFG和IFG肥胖者的β细胞功能,但2年内有恶化趋势。
  • IFG者减重后2年β细胞功能仍显著优于基线,是最可能获益的亚群。

研究设计与样本

  • 58例BMI≥35 kg/m²肥胖者(NFG 14例、IFG 24例、T2DM 20例)及13例正常体重NFG者。
  • 所有肥胖者于减重后3-6个月复测,其中27例于2年时复测。
  • 采用混合餐耐量试验估算胰岛素敏感性S(I)、分泌Φ及模型校正的β细胞功能。

主要发现

  • 3-6个月减重20 kg、BMI下降6 kg/m²后,所有肥胖者S(I)改善。
  • NFG和IFG者Φ下降,T2DM者Φ呈下降趋势。
  • NFG者β细胞功能改善,IFG者呈改善趋势;2年时NFG和T2DM者β细胞功能恶化。
  • 2年时IFG者β细胞功能仍显著优于基线。

关键数值与推荐

  • 肥胖组BMI≥35 kg/m²,分为NFG、IFG和T2DM三个亚组。
  • 短期减重幅度为体重下降20 kg、BMI下降6 kg/m²。

临床怎么用

  • 对严重肥胖合并IFG者,应积极推行减重以改善β细胞功能。
  • 减重获益需长期维持,2年内β细胞功能可能回落。

局限性

  • 2年复测样本量仅27例,长期数据有限。
  • 非随机对照设计,无法完全区分减重与自然病程的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In people with obesity, β-cell function may adapt to insulin resistance. We describe β-cell function in people with severe obesity and normal fasting glucose (NFG), impaired fasting glucose (IFG), and type 2 diabetes (T2DM), as assessed before, 3 to 6 months after, and 2 years after medical weight loss to describe its effects on insulin sensitivity, insulin secretion, and β-cell function. METHODS: Fifty-eight participants with body mass index (BMI) ≥ 35 kg/m2 (14 with NFG, 24 with IFG, and 20 with T2DM) and 13 normal weight participants with NFG underwent mixed meal tolerance tests to estimate insulin sensitivity (S[I]), insulin secretion (Φ), and β-cell function assessed as model-based Φ adjusted for S(I). All 58 obese participants were restudied at 3 to 6 months and 27 were restudied at 2 years. RESULTS: At 3 to 6 months, after a 20-kg weight loss and a decrease in BMI of 6 kg/m2, S(I) improved in all obese participants, Φ decreased in obese participants with NFG and IFG and tended to decrease in obese participants with T2DM, and β-cell function improved in obese participants with NFG and tended to improve in obese participants with IFG. At 2 years, β-cell function deteriorated in participants with NFG and T2DM but remained significantly better in participants with IFG compared to baseline. CONCLUSIONS: Short-term weight loss improves β-cell function in participants with NFG and IFG, but β-cell function tends to deteriorate over 2 years. In participants with IFG, weight loss improves longer-term β-cell function relative to baseline and likely relative to no intervention, suggesting that obese people with IFG are a subpopulation whose β-cell function is most likely to benefit from weight loss.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Rothberg AE, Herman WH, Wu C, et al. Weight Loss Improves β-Cell Function in People With Severe Obesity and Impaired Fasting Glucose: A Window of Opportunity. J Clin Endocrinol Metab. 2020. PMID: 31720686. doi:10.1210/clinem/dgz189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。